Insulet stock steadies after August 5 earnings beat

Insulet stock is trading with a $10.19 billion market cap as investors weigh its August 5 quarter, which delivered $801.70 million in revenue and $1.66 in EPS.

Insulet Corporation stock (US45784P1012) is trading around $146.87 with a market cap of $10.19 billion as of August 21, 2026, while the latest quarter delivered $801.70 million in revenue and $1.66 in adjusted EPS. The August 5 report also showed revenue growth of 23.5% year over year and EPS ahead of the $1.47 consensus by $0.19.

Quarterly numbers still matter

The quarter ended June 30, 2026 gave Insulet a fresh operating benchmark, with net margin at 12.29% and return on equity at 29.29% in the same earnings update. Those figures sit alongside FY 2026 guidance for EPS of 6.460, a level that frames the next stretch of trading.

Insulet's current valuation looks less stretched than its longer history, with the stock priced at 27.45 times earnings in recent market data, versus a 52-week range of $126.40 to $354.88. The gap between the present price and the yearly high remains wide, which keeps valuation and execution on the same page for investors.

What the market sees

Market data from August 20, 2026 put the shares at $151.51, below the 50-day moving average of $154.75 and well under the 200-day moving average of $185.83. Another market snapshot on August 21 showed $146.87 at the open, so the stock has been moving inside a lower band after the earnings release.

The current analyst backdrop is cautious but not bearish, with an average rating of Hold and a consensus target price of $195.40 in recent market coverage. That leaves the shares materially below the consensus target, even after the post-earnings stabilization.

Omnipod remains the core

Insulet's main product line remains Omnipod, the tubeless insulin delivery system that anchors the company's revenue base and supports its consumables model. The latest earnings math matters because the installed base and refill cycle are central to how the business compounds through each quarter.

Stock levels to watch

As of August 21, 2026, Insulet stock is quoted at $146.87 in USD, with a market cap of $10.19 billion and a 52-week range of $126.40 to $354.88. The next reported earnings date has not been confirmed in the available data.

Fact box

Company: Insulet Corporation
ISIN: US45784P1012
Ticker: PODD
Exchange: NASDAQ
Price (as of August 21, 2026): $146.87 USD
Market cap: $10.19 billion
Sector / Industry: Health Care / Medical Instruments & Supplies
Index membership: S&P 500